Unknown

Dataset Information

0

Rapid induction onto extended-release injectable buprenorphine following opioid overdose: A case series.


ABSTRACT:

Background

Buprenorphine treatment has been associated with reduced non-prescribed opioid use and opioid related overdose (OD). We evaluated initial outcomes of rapid induction onto extended-release injectable buprenorphine (BUP-XR) within 7 days of emergency department presentation for unintentional OD.

Methods

Between February 2019-February 2021, N = 19 patients with opioid use disorder received buprenorphine/naloxone (4/1 mg), followed by BUP-XR (300 mg) at induction and continued BUP-XR outpatient for 6 months. Primary outcomes included adverse events, repeat OD, and death.

Results

For patients who received at least one dose of BUP-XR, there were no treatment related serious adverse events or symptoms of precipitated withdrawal. In addition, there were no repeat visits for ODs or deaths within 6 months of the initial OD.

Discussion

These preliminary findings support the need for larger controlled clinical trials to examine the safety and efficacy of rapid induction of BUP-XR in patients with opioid use disorder at high risk of opioid OD. Rapid induction onto long-lasting injectable buprenorphine may be a promising and protective treatment approach in the future.

SUBMITTER: Ochalek TA 

PROVIDER: S-EPMC10073633 | biostudies-literature | 2023 Jun

REPOSITORIES: biostudies-literature

altmetric image

Publications

Rapid induction onto extended-release injectable buprenorphine following opioid overdose: A case series.

Ochalek Taylor A TA   Ringwood Katy J KJ   Davis Theresa T TT   Gal Tamas S TS   Wills Brandon K BK   Sabo Roy T RT   Keyser-Marcus Lori L   Martin Caitlin E CE   Polak Kathryn K   Cumpston Kirk L KL   Moeller F Gerard FG  

Drug and alcohol dependence reports 20230316


<h4>Background</h4>Buprenorphine treatment has been associated with reduced non-prescribed opioid use and opioid related overdose (OD). We evaluated initial outcomes of rapid induction onto extended-release injectable buprenorphine (BUP-XR) within 7 days of emergency department presentation for unintentional OD.<h4>Methods</h4>Between February 2019-February 2021, <i>N</i> = 19 patients with opioid use disorder received buprenorphine/naloxone (4/1 mg), followed by BUP-XR (300 mg) at induction and  ...[more]

Similar Datasets

| S-EPMC8004552 | biostudies-literature
| S-EPMC11231806 | biostudies-literature
| S-EPMC10822018 | biostudies-literature
| S-EPMC3225026 | biostudies-literature
| S-EPMC6583381 | biostudies-literature
| S-EPMC8459386 | biostudies-literature
| S-EPMC10500382 | biostudies-literature
| S-EPMC5993595 | biostudies-literature
| S-EPMC6581635 | biostudies-literature
| S-EPMC7433932 | biostudies-literature